Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) closed its last session at $18.83 with the change of +2.06%. The market capitalization of the company is $1.96B with an average Volume of 866.79 thousand shares. The stock currently has its 52-Week High range of $19.19 and 52-week low range of $7.65. The Price to Book (P/B) ratio stands at 8.82. The stock traded total quantity of 1.8 million shares.
Currently Lexicon Pharmaceuticals, Inc. (LXRX) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “4″ Analysts”. “0” rated “Sell” for the company. “3” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $24.33 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $33.00 however minimum price target advised by analysts is $20.00. The Median price target for the stock is measured at $23.00.
Presently, Analysts decided consensus EPS estimate of $-0.47 for present quarter and one month ago projected EPS estimate was at $-0.47. If we take a look at back 3 month ago, consensus EPS estimate was $-0.49.
A current consensus EPS estimate for next quarter is at $-0.36 and 3 month ago EPS forecast was $-0.33. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.36.
For current fiscal year, most recent EPS estimate is set at $-1.49 based on Analyst consensus and three month ago consensus EPS opinions was at $-1.46. During period one month ago, consensus EPS forecast was decided at $-1.50.
A current consensus EPS projection for next fiscal year is observed at $-1.52 and one month ago consensus EPS forecast was at $-1.53. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-1.52 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 4 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 3 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 2 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.